Clinical Trial Update: Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating olaparib, a PARP inhibitor, with intravenous ascorbate for castration-resistant prostate cancer; the trial is terminated and results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ascorbic acid (intravenous) (ascorbic acid)
• Olaparib (Olaparib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-01-29